AstraZeneca and Global Transparency

Home / Sustainability / Ethics and transparency / AstraZeneca and Global Transparency

Our Approach

AstraZeneca strongly believes that interactions with Health Care Providers (HCPs) and Healthcare Organisations (HCOs) positively influence the quality of patient treatment and the value of medical research.

To provide patients with optimal treatment options, HCPs need to stay informed about the latest developments with current and potential new medicines. The pharmaceutical industry has a duty to provide this information.

HCPs in turn provide the industry with insights into how to improve medicines by feeding back on how they work in real world settings.

We also recognize that patients expect transparency around these relationships to feel confident that HCPs are impartial and always recommend the most appropriate treatment options.

We believe that regulations such as US Open Payments, the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure code, and others across the globe, which require companies to disclose payments and transfers of value made to HCPs and HCOs, will provide greater transparency around these already well-regulated relationships.



Disclosure of Payments and Transfers

The payments and transfers of value disclosed here were made for activities such as providing professional advice about how medicines are used in practice, sharing professional expertise at medical education meetings, taking part in advisory boards, research and educational grants.



AstraZeneca Europe

To download the assumptions and interpretations of the EFPIA Code of Practice for each of our markets, and to download market-level disclosure reports, please click on the country links below.

The 2024 Self Certification Letter affirms AstraZeneca’s commitment to the principles of the EFPIA Code of Practice.

 



Alexion Europe



US

For information about US Open Payments, please visit our Physician engagement page or the US Open Payments page managed by the Centers for Medicaid and Medicare Services (CMS).

Alternatively, for information regarding other US specific disclosure activity, please visit the US Corporate Transparency page.


Astrazeneca Asia Pacific



Alexion Asia Pacific



Latin America



Middle East & Africa


Last updated May 2024